Camizestrant Clinical Trials
6 recruitingDrug
Phase 33Phase 23Phase 11
Showing 1–6 of 6 trials
Recruiting
Phase 2
Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer
Advanced Breast Cancer
AstraZeneca24 enrolled6 locationsNCT07427394
Recruiting
Phase 2
Efficacy and Safety of Camizestrant Plus Ribociclib in Patients With Breast Cancer
Breast CancerHormon Receptor Positive Breast Cancer
MedSIR150 enrolled16 locationsNCT07195227
Recruiting
Phase 3
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
Breast Cancer (Early Breast Cancer)
AstraZeneca5,500 enrolled794 locationsNCT05952557
Recruiting
Phase 3
Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
Advanced Breast Cancer
AstraZeneca500 enrolled298 locationsNCT06380751
Recruiting
Phase 1Phase 2
A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors
ER+ HER2- Advanced Breast CancerHigh-grade Serous Ovarian Cancer (HGSOC)
AstraZeneca564 enrolled14 locationsNCT06188520
Recruiting
Phase 3
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
Breast Cancer (Early Breast Cancer)
AstraZeneca4,300 enrolled711 locationsNCT05774951